Recently, Voyager Therapeutics (VYGR) announced that it had generated a partnership with AbbVie (ABBV) for Parkinson's disease and other neurodegenerative diseases. This deal is expected to be worth up to >$1 billion. I believe that Voyager will greatly benefit from having such a strong partner to help fund some of the clinical development. In addition, Voyager is nearing data in Q2 of 2019 for its VY-AADC gene therapy product treating patients with Parkinson's.
Large Deal For Neurodegenerative Diseases
According to the agreement, Voyager is going to be responsible to research the